A safety study of perioperative olprinone administration for liver resection

A safety study of perioperative olprinone administration for liver resection - A safety study of olprinone for liver resection

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004975

Enrollment

Registered

2011-05-01

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary liver cancer Metastatic liver cancer

Interventions

Perioperative olprinone administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Primary or metastatic liver cancer confirmed by clinical or histopathological examinations 2) Resectable liver cancer 3) Child Pugh classification A or B 4) Performance status 0-1 5) Adequate organ function 6) Ability of self-determination 7) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Biliary reconstruction 2) Gastrointestinal resection and lymphatic dissection 3) Preoperative percutaneous transhepatic portal embolization 4) Active double cancer 5) Serious complications such as heart or renal failure 6) A history of severe hypersensitivity

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Protective effects on the liver	—

Countries

Japan

Contacts

Public ContactKenya Yamanaka

Kyoto University Hospital Department of Surgery

kenya.y@hx5.ecs.kyoto-u.ac.jp075-751-3242

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026